<DOC>
	<DOCNO>NCT02778399</DOCNO>
	<brief_summary>The primary objective study assess efficacy safety range oral dos OBE2109 versus placebo , reduce endometriosis associate pain .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety OBE2109 Subjects With Endometriosis</brief_title>
	<detailed_description>The study prospective , dose-finding , randomize , parallel group , double-blind , placebo-controlled phase 2b study investigate efficacy safety OBE2109 treatment 330 woman moderate-to-severe endometriosis associate pain . Subject randomize one 6 treatment group 1:1:1:1:1:1 ratio ( 1 placebo group , 5 dose group different dosage/regimen ) .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Key The subject must surgically available histologically confirm pelvic endometriosis 7 year screen . The subject moderate severe endometriosisassociated pain screen period . The subject regular menstrual cycle . The subject BMI ≥ 18 kg/m2 ≤ 39 kg/m2 screen visit . Key The subject pregnant breast feed planning pregnancy within duration treatment period study . The subject interventional surgery endometriosis perform within period 60 day screen . The subject respond prior treatment gonadotropin release hormone ( GnRH ) agonists GnRH antagonist endometriosis . The subject history , know osteoporosis metabolic bone disease . The subject chronic pelvic pain cause endometriosis require chronic analgesic / therapy , would interfere assessment endometriosis relate pain .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pelvic Pain</keyword>
	<keyword>Endometriosis</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Dyspareunia</keyword>
</DOC>